Inclusion Criteria:

          -  Part A and Part B: Has histologically or cytologically-confirmed metastatic solid
             tumor.

          -  Has measurable disease by immune-related Response Evaluation Criteria in Solid Tumors
             (irRECIST) 1.1 criteria.

          -  Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
             Performance Scale.

          -  Demonstrates adequate organ function.

          -  If female, is not pregnant or breastfeeding, and if of child-bearing potential, is
             willing to use an adequate method of contraception for the course of the study through
             120 days after the last dose of study drug.

          -  If male with a female partner(s) of child-bearing potential, both must agree to use an
             adequate method of contraception starting with the first dose of study drug through 95
             days after the last dose of study drug.

        Exclusion Criteria:

          -  Has had chemotherapy, radiation or biological cancer therapy within 4 weeks prior to
             the first dose of study drug, or has not recovered to Common Terminology Criteria for
             Adverse Events (CTCAE) Grade 0 or 1 from the AEs due to cancer therapeutics
             administered more than 4 weeks earlier (this includes participants with previous
             immunomodulatory therapy with residual immune-related [ir]AEs).

          -  Is currently participating and receiving study therapy or has participated in a study
             of an investigational agent and received study therapy or used an investigational
             device within 4 weeks of the first dose of study drug.

          -  Has received previous treatment with another agent targeting the lymphocyte-activation
             gene 3 (LAG-3) receptor.

          -  Has received previous treatment with an immunomodulatory therapy (e.g. anti-programmed
             cell death-1/anti-programmed cell death-ligand 1 [anti-PD-1/anti-PD-L1] or cytotoxic
             T-lymphocyte-associated protein 4 [CTLA 4] agent) and was discontinued from that
             therapy due to a Grade 3 or higher irAE.

          -  Is expected to require any other form of antineoplastic therapy while on study.

          -  Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
             in excess of replacement doses, or on any other form of immunosuppressive medication.

          -  Has a history of a previous, additional malignancy, unless potentially curative
             treatment has been completed, with no evidence of malignancy for 5 years. Time frame
             exceptions include successful definitive resection of basal cell carcinoma of the
             skin, superficial bladder cancer or in situ cervical cancer, or other in situ cancers.

          -  Has known active central nervous system (CNS) metastases and/or carcinomatous
             meningitis.

          -  Has had a severe hypersensitivity reaction to treatment with another monoclonal
             antibody.

          -  Has an active autoimmune disease or a documented history of autoimmune disease, except
             vitiligo or resolved childhood asthma/atopy.

          -  Has an active infection requiring therapy.

          -  Has history of (non-infectious) pneumonitis that required steroids or has current
             pneumonitis.

          -  Has had a prior stem cell or bone marrow transplant.

          -  Has a known history of or screens positive for Human Immunodeficiency Virus (HIV),
             active chronic or acute Hepatitis B or Hepatitis C.

          -  Has known psychiatric or substance abuse disorders that would interfere with
             cooperation with the requirements of the study.

          -  Is a regular user as determined by investigator judgment (including "recreational
             use") of any illicit drugs or has a recent history (within the last year) of substance
             abuse (including alcohol), at the time of signing informed consent.

          -  Has symptomatic ascites or pleural effusion. A participant who is clinically stable
             following treatment for these conditions (including therapeutic thoraco- or
             paracentesis) is eligible.

          -  Has clinically significant heart disease that affects normal activities.

          -  Has received a live-virus vaccine within 30 days of planned start of study drug.
             Seasonal flu vaccines that do not contain live virus are permitted.